LARP6 and cancer: Although the safety, efficacy, and pharmacological properties of this specific compound may not be satisfactory for therapeutic use, our results demonstrate the plausibility of therapeutic targeting of LARP6 by small-molecule inhibitors in the context of inhibiting ribosome biogenesis in mesenchymal/EMT associated cancer subtypes.